Drug profile · INN
tofacitinib
XELJANZ
tofacitinib (XELJANZ) is a janus kinase (jak) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — tofacitinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tofacitinib (XELJANZ) is a janus kinase (jak) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Janus Kinase (JAK) inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Related & competitor drugs
Frequently asked questions
What is tofacitinib?
tofacitinib (XELJANZ) is a janus kinase (jak) inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tofacitinib?
XELJANZ is a marketed brand name for tofacitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tofacitinib?
tofacitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.